Changes in serum levels of pro- and anti-inflammatory cytokines in women with papillomavirus infection before and after therapy

Abstract

The group of papillomaviruses is one of the most common viral infections among sexually transmitted diseases in the young population. A long, sluggish inflammatory process significantly worsens adequate pre-gravidar preparation. Along with papillomavirus infection, herpesvirus and chlamydia infections are the most frequent associations. Many authors believe that PVI reveals dysregulation of pro- and anti-inflammatory cytokines in the blood serum. Currently, there are no uniform standards for the management and treatment of women with papillomavirus infection without pronounced clinical manifestations to prevent morphofunctional disorders of the genitourinary system leading to reproductive disorders. But most authors believe that the use of antiviral and immunomodulatory drugs is the main method of therapy against the proliferation of pathogens in the body. The aim of the study was to compare changes in the levels of IL-17, IL-12 p70, IL-12 p40, IL-13 and TFR-β1 in the blood serum of women with papillomavirus infection before and after therapy with Inosine pranobex (IP) and Solanum tuberosum (ST). Materials and methods: a survey of 137 patients with papillomavirus infection treated with drugs with the active substance Inosine pranobex and Solanum tuberosum was conducted. The levels of IL-17, IL-12 p70, IL-12 p40, IL-13, and TFR-β1 in blood serum were determined using specific reagents from R&D Diagnostics Inc. (USA). Results. Changes in pro- and anti-inflammatory cytokines before therapy: decrease — IL-12 p70, p40, increase — IL-13, IL-17 and TFR-β1. After therapy, the following changes were revealed in the group of patients exclusively with PVI infection when using the drug of synthetic origin IP: the levels of IL-12 p70, IL-12 p40 and a decrease in IL-13 and TFR-β1 increased, while with ST therapy: an increase in IL-12 p70, IL-12 p40 and a decrease in IL-13 and TFR-β1. With IP therapy, patients with HPV+HVI registered an increase in IL-12 p70, IL-12 p40 and a decrease in IL-13, while TFR-β1 did not change, and with ST therapy, IL-12 p70, IL-12 p40 also increased and IL-13 decreased, TFR-β1 remained unchanged. In the group of women with HPV+chlamydia infection, an increase in IL-12 p70, IL-12 p40 and a decrease in IL-13 and TFR-β1 with IP therapy, and an increase in IL-12 p70, IL-12 p40 and a decrease in IL-13 and TFR-β1 with ST therapy were shown. In all groups of patients, IL-17 remained high after therapy without a statistically significant difference between the subgroups. In the groups of patients treated with IP, a predominant normalization of the degree of immune disorders was recorded.